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ABSTRACT
Lipid metabolism plays an essential role in carcinogenesis due to the requirements 
of tumoral cells to sustain increased structural, energetic and biosynthetic precursor 
demands for cell proliferation. We investigated the association between expression 
of lipid metabolism-related genes and clinical outcome in intermediate-stage colon 
cancer patients with the aim of identifying a metabolic profile associated with greater 
malignancy and increased risk of relapse. Expression profile of 70 lipid metabolism-
related genes was determined in 77 patients with stage II colon cancer. Cox regression 
analyses using c-index methodology was applied to identify a metabolic-related 
signature associated to prognosis. The metabolic signature was further confirmed in 
two independent validation sets of 120 patients and additionally, in a group of 264 
patients from a public database. The combined analysis of these 4 genes, ABCA1, 
ACSL1, AGPAT1 and SCD, constitutes a metabolic-signature (ColoLipidGene) able to 
accurately stratify stage II colon cancer patients with 5-fold higher risk of relapse with 
strong statistical power in the four independent groups of patients. The identification 
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of a group of 4 genes that predict survival in intermediate-stage colon cancer patients 
allows delineation of a high-risk group that may benefit from adjuvant therapy, and 
avoids the toxic and unnecessary chemotherapy in patients classified as low-risk group.
INTRODUCTION
Colorectal cancer (CRC) is one of the main causes 
for morbidity and mortality worldwide, and represents 
the fourth most common cancer in men and the third in 
women [1, 2].
Prediction of outcome in CRC is based on the TNM 
staging classification, which constitutes a good predictor of 
survival in patients with TNM Stage I and IV with survival 
rates of 90–95% and < 10%, respectively [3]. However, in 
patients with intermediate TNM Stages II and III, within 
survival rates of 70–85% and 40–80% respectively [3], 
the prediction of outcome is often imprecise with relevant 
consequences in the clinical outcome and quality of life of 
patients. Consequently, identification of novel biomarkers 
that improve the prognostic ability in these CRC stages 
is needed, and constitutes a main objective of scientific 
research in the area [4–7].
Recently, altered metabolism has been added to the 
list of core hallmarks of cancer [8]. It is well known that 
lipid metabolism plays a crucial role in different types of 
cancer due to the special requirements of cancer cells to 
sustain the additional energetic and biosynthetic precursor 
demands for cell proliferation [9, 10]. These changes in 
lipid metabolism affect essential cellular processes [10, 11], 
and overexpression of lipogenic enzymes has been reported 
as a common characteristic of many cancers [11–13]. In 
fact, key enzymes involved in lipid-metabolic pathways 
are differentially expressed in normal and tumoral tissues, 
and some of them have been individually proposed as 
prognosis markers in cancer [12]. However, the analysis 
of dysregulated expression of lipid metabolic enzymes as 
a whole in carcinogenesis remains to be established [14].
Here, for the first time, gene expression levels of a 
wide-range of lipid metabolism-related genes to identify 
different metabolic patterns conferring tumor energetic 
advantage consequently associated with worse clinical 
outcome, are analyzed in stage II CRC patients.
RESULTS
Global analysis of lipid metabolism-related 
genes in stage II-CRC patients
With the aim of classifying patients within the same 
clinicopathological stage according to their molecular 
metabolic characteristics, we carried out a global and 
simultaneous analysis of lipid metabolism-related genes 
in a training group of 77 samples of patients with stage II-
CRC patients. Median follow-up of these patients was 71.5 
months. The 3-year DFS was 72.3% and we identified local 
and/or distant recurrence in 22 patients (28.57%), of which 13 
patients (59.01%) died of CRC. Thirty patients (38.96%) did 
not receive adjuvant treatment, whereas 47 patients (61.04%) 
received chemotherapy based on 5FU-LV (Fluoracil-
Leucovorin) treatment. List of 70 lipid metabolism-related 
genes selected by their crucial regulatory role of lipid pathways 
and their involvement in different aspects of lipid metabolism 
is shown in Table 1. Detailed clinico-histopathological 
characteristics of these patients are summarized in Table 2.
Results showed that 16 out of the 70 genes analyzed 
in this study were differentially distributed in the tumors 
with a putative association between expression levels and 
worse clinical outcome in this training group of stage II 
CRC patients (Table 1), suggesting that specific pathways 
of lipid metabolism might be specially related to increased 
malignancy.
Development of a metabolic-related gene 
expression signature
The putative interactions among the different genes 
and the combination of different metabolic patterns were 
assayed, and models constituting a prognostic signature 
were constructed selecting the multivariate model with 
largest c-index (0.72) using 100 times 5-fold cross-
validation (CV). A gene expression signature composed 
of the combination of 4 lipid metabolism-related genes 
was selected due to its high score to predict DFS, and 
designated as ColoLipidGene signature. ColoLipidGene, 
constituted by the combination of ABCA1, ACSL1, 
AGPAT1 and SCD, genes involved in lipid transport, 
fatty acid activation and phospholipid-related signaling, 
was able to significantly predict risk of relapse of CRC 
patients within the same stage II with a HR (95% CI): 
4.65 (1.98–10.93), log-rank p < 0.001 (Figure 1). 3-year 
DFS in patients from High risk group classified by 
ColoLipidGene was 41% (95% CI: 0.25–0.68) compared 
with 85% (95% CI: 0.76–0.95) in patients from low 
risk group. To evaluate whether ColoLipidGene might 
constitute an independent prognostic classifier, clinical 
and histopathological data were included in both 
univariate and multivariate Cox regression analyses. In 
univariate analysis, tumor size (T), vascular invasion, 
perineural invasion and bowel obstruction/perforation 
were the strongest clinical variables associated with 
prognosis in these patients (Table 3), which were included 
in the multivariate analysis, together with age > 70 as 
main nonmodifiable risk factor. Results obtained in the 
multivariate analysis revealed that ColoLipidGene was 
an independent prognostic classifier for DFS with 4-fold 
increased risk of relapse for stage II CRC patients positive 
for this molecular test [HR (95% CI): 3.94 (1.54–10.11), 
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Table 1: Lipid metabolism-related genes include in the study. HR (95% CI): genes with significant 
association with tumor progression in the training group.
Metabolic Pathway Symbol Gene name Chromosome 
location
HR (95% CI) P
Adipocytokine 
signaling and immune 
homeostasis
ADIPOQ
Adiponectin, C1Q and collagen 
domain containing 3q27
CFI Complement factor I 4q25
PPARGC1A
Peroxisome proliferator-activated 
receptor gamma, coactivator 1 alpha 4p15.1
SLC2A4
Solute carrier family 2 (facilitated 
glucose transporter), member 4 17p13
Bile acid biosynthesis ABCB11 ATP-binding cassette, sub-family B 
(MDR/TAP), member 11
2q24
SLC10A2
Solute carrier family 10 (sodium/bile 
acid cotransporter family), member 2 13q33
SLCO1A2
Solute carrier organic anion 
transporter family, member 1A2 12p12
SLCO1B1
Solute carrier organic anion 
transporter family, member 1B1 12p
Endocytosis of 
specific ligands
LDLR Low density lipoprotein receptor 19p13.2
Fatty acid 
biosynthesis ACACA
Acetyl-Coenzyme A carboxylase 
alpha 17q21
FADS1 Fatty acid desaturase 1 11q12.2–q13.1
FADS2 Fatty acid desaturase 2 11q12.2 0.39 (0.16–0.93) 0.0298
FADS3 Fatty acid desaturase 3 11q12–q13.1
FADS6
Fatty acid desaturase domain family, 
member 6 17q25.1
FASN Fatty acid synthase 17q25
SCD
Stearoyl-CoA desaturase (delta-9-
desaturase) 10q24.31 3.57 (1.06–12.08) 0.0181
SCD5 Stearoyl-CoA desaturase 5 4q21.22
Fatty acid β-oxidation ACADM
Acyl-Coenzyme A dehydrogenase, 
C-4 to C-12 straight chain
1p31 4.39 (1.03–18.8) 0.0152
ACAT1 Acetyl-Coenzyme A acetyltransferase 1 11q22.3
ACLY ATP citrate lyase 17q21.2
ACSM4 Acyl-CoA synthetase medium-chain family member 4 12p13.31
ACSS2 Acyl-CoA synthetase short-chain family member 2 20q11.22
ECHS1 Enoyl Coenzyme A hydratase, short chain, 1, mitochondrial 10q26.2–q26.3
HADH
Hydroxyacyl-Coenzyme A 
dehydrogenase 4q22–q26
(Continued)
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Metabolic Pathway Symbol Gene name Chromosome 
location
HR (95% CI) P
HMGCL
3-Hydroxymethyl-3-methylglutaryl-
Coenzyme A lyase 1p36.1-p35 2.83 (1.04–7.69) 0.0271
HMGCS2
3-Hydroxy-3-methylglutaryl-Coenzyme 
A synthase 2 (mitochondrial) 1p13-p12
3.81 (0.89–
16.31) 0.031
PPA1 Pyrophosphatase (inorganic) 1 10q11.1–q24
SLC25A20
Solute carrier family 25 (carnitine/
acylcarnitine translocase), member 20 3p21.31
Lipid metabolism in 
peroxisomes ACOT8 Acyl-CoA thioesterase 8 20q13.12
ACOX2
Acyl-Coenzyme A oxidase 2, 
branched chain 3p14.3 2.9 (1.21–6.93) 0.014
ACOX3
Acyl-Coenzyme A oxidase 3, 
pristanoyl 4p15.3 2.4 (1.03–5.58) 0.0474
ACSL1
Acyl-CoA synthetase long-chain 
family member 1 4q35 2.93 (1.26–6.81) 0.0128
ACSL3
Acyl-CoA synthetase long-chain 
family member 3 2q34–q35
ACSL4
Acyl-CoA synthetase long-chain 
family member 4 Xq22.3–q23
4.92 (2.09–
11.62) 0.0003
AGPS Alkylglycerone phosphate synthase 2q31.2
AMACR Alpha-methylacyl-CoA racemase 5p13
FAR1 Fatty acyl CoA reductase 1 11p15.2
FAR2 Fatty acyl CoA reductase 2 12p11.22
GNPAT Glyceronephosphate O-acyltransferase 1q42
HSD17B4
Hydroxysteroid (17-beta) 
dehydrogenase 4 5q21 2.64 (1.11–6.29) 0.025
SCP2 Sterol carrier protein 2 1p32
Phospholipids 
metabolism LIPH Lipase, member H 3q27
MBOAT1
Membrane bound O-acyltransferase 
domain containing 1 6p22.3
MBOAT2
Membrane bound O-acyltransferase 
domain containing 2 2p25.1
PPAR signaling CYP7A1 Cytochrome P450, family 7, subfamily A, polypeptide 1 8q11-q12
FABP4
Fatty acid binding protein 4, 
adipocyte 8q21
PLIN1 Perilipin 1 15q26
PPARD
Peroxisome proliferator-activated 
receptor delta 6p21.2
PPARG
Peroxisome proliferator-activated 
receptor gamma 3p25
(Continued )
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Metabolic Pathway Symbol Gene name Chromosome 
location
HR (95% CI) P
Cholesterol transport ABCA1 ATP-binding cassette, sub-family A (ABC1), member 1 9q31.1 3.08 (1.25–7.56) 0.010
ABCG5
ATP-binding cassette, sub-family G 
(WHITE), member 5 2p21
Triacylglycerol 
metabolism AGPAT1
1-Acylglycerol-3-phosphate 
O-acyltransferase 1 (lysophosphatidic 
acid acyltransferase, alpha)
6p21.3 4.31 (1.8–10.32) 0.0008
AGPAT2
1-Acylglycerol-3-phosphate 
O-acyltransferase 2 (lysophosphatidic 
acid acyltransferase, beta)
9q34.3 3.37 (1.45–7.81) 0.0052
AGPAT3
1-Acylglycerol-3-phosphate 
O-acyltransferase 3
21q22.3 3.78 (1.28–11.17) 0.0068
AGPAT4
1-Acylglycerol-3-phosphate 
O-acyltransferase 4 (lysophosphatidic 
acid acyltransferase, delta)
6q26
AGPAT5
1-Acylglycerol-3-phosphate 
O-acyltransferase 5 (lysophosphatidic 
acid acyltransferase, epsilon)
8p23.1
DGAT1
Diacylglycerol O-acyltransferase 
homolog 1 (mouse) 8q24.3
LIPG Lipase, endothelial 18q21.1
MGLL Monoglyceride lipase 3q21.3
Regulation of the 
hepatocyte growth 
factor (HGF)
SPINT1 Serine peptidase inhibitor, Kunitz type 1 15q15.1 3.96 (1.17–13.41) 0.010
ST14 Suppression of tumorigenicity 14 (colon carcinoma) 11q24-q25
Receptors and 
basement membrane 
glycoproteins
MC3R Melanocortin 3 receptor 20q13.2-q13.3
MC4R Melanocortin 4 receptor 18q22
NID1 Nidogen 1 1q43 2.76 (0.93–8.17) 0.043
NID2 Nidogen 2 (osteonidogen) 14q22.1
Biosynthesis 
of metabolic 
components
GCG Glucagon 2q36-q37
MGAT1
Mannosyl (alpha-1,3-)-
glycoprotein beta-1,2-N-
acetylglucosaminyltransferase
5q35
NAMPT Nicotinamide phosphoribosyltransferase 7q22.3
Fatty acid and 
guanine nucleotide-
binding proteins
FABP2 Fatty acid binding protein 2, intestinal 4q28-q31
GNB3
Guanine nucleotide binding protein 
(G protein), beta polypeptide 3
12p13
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Table 2: Detailed clinical and histopathological characteristics of patients included in the study
Characteristics Stage II CRC
Training group Validation group I Validation group II
n° of Patients (%) n° of Patients (%) n° of Patients (%)
Total sample size (n) 77 (100) 119 (100) 120 (100)
Age at Diagnosis (years)
Mean 68·22 66·08 —
Median 69 66 —
Age Range 32–86 26–91 33–88
≤50 3 (3·90) 15 (12·60) 15 (12·5)
50–70 39 (50·65) 58 (48·74) 63 (52·5)
≥70 35 (45·45) 46 (38·66) 42 (35)
Sex
Female 33 (42·86) 54 (45·38) 60 (50)
Male 44 (57·14) 65 (54·62) 60 (50)
Stage
IIA (T3 N0 M0) 56 (72·73) 70 (58·82) 99 (82·5)
IIB (T4 N0 M0) 21 (27·27) 49 (41·18) 21 (17·5)
Regional Lymph Node Metastasis
No Lymph node 
involvement (N0) 77 (100) 119 (100) 120 (100)
1–3 Lymph node 
involvement (N1)
≥4 Lymph node 
involvement (N2)
Could not be assessed 
(Nx)
Total Lymph Nodes Resected
Mean Lymph nodes 
resected 12·09 14·20 17·38
Range of Lymph 
nodes examined 1–29 0–43 3–43
≤12 46 (59·7) 54 (45·4) 32 (26·67)
>12 30 −39 62 (52·1) 87 (72·5)
Unknown 1 (1·3) 3 (2·5) 1 (0·83)
Location of Primary
Cecum and Ileocecal 
Valve 2 (2·6) 13 (10·92) 9 (7·5)
Acending colon and 
Hepatic flexure
29 (37·66) 29 (24·37) 24 (20)
Transverse colon 6 (7·79) 6 (5·04) 6 (5)
(Continued )
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p = 0.005; Table 4], establishing an association between 
high expression levels of these four genes that constituted 
ColoLipidGene and worse clinical outcome in these stage 
II CRC patients.
ColoLipidGene validation
In order to confirm the association of these four lipid 
metabolism-related genes with the potential aggressiveness 
of the tumor, we evaluated lipidic gene expression analysis 
as previously indicated in an independent validation set 
of 119 stage II CRC patients (validation group I). Median 
follow-up and 3-year DFS of these patients was 43 months 
and 86.1% respectively. Eighteen out of the 119 patients 
relapsed with local and/or distant metastasis (15.3%), of 
which 11 patients (61.1%) died due to CRC. Forty-three 
patients (36.13%) did not receive adjuvant treatment, 
whereas 76 patients (63.87%) received chemotherapy 
based on Xelox or Folfox4 treatment Table 2). Gene 
expression analysis in the validation group confirmed 
the potential value of the 4-gene expression signature 
ColoLipidGene (c-index = 0.77) as a prognostic biomarker 
to identify stage II CRC patients at high risk of relapse 
[HR (95% CI): 6.57 (2.15–20.02), log-rank p < 0.001; 
Figure 1, Table 4]. Thus, 3-year DFS in patients from High 
risk group classified by this gene expression profile was 
69% (95% CI: 0.57–0.84) compared with 97% (95% CI: 
0.93–1) in patients from low risk group in the validation 
Characteristics Stage II CRC
Training group Validation group I Validation group II
n° of Patients (%) n° of Patients (%) n° of Patients (%)
Splenic flexure and 
Descending colon
5 (6·49) 17 (14·29) 6 (5)
Sigmoid colon and 
rectosigmoid junction 34 (44·16) 54 (45·38) 75 (62·5)
Rectum 1 (1·3) 0 0
Grade/Differentiation
Well 5 (6·49) 10 (8·4) 11 (9·17)
Moderately 66 (85·71) 95 (79·8) 101 (84·16)
Poor 5 (6·49) 10 (8·4) 8 (6·67)
Unknown 1 (1·3) 4 (3·4) 0
Bowel Obstruction/Perforation
Yes 10 (12·99) 45 (37·82) 30 (25)
No 67 (87·01) 74 (62·18) 90 (75)
Other Histological Features
Perineural invasion 12 (15·58) 25 (21) 20 (16·67)
Vascular invasion 22 (28·57) 31 (26·05) 14 (11·67)
Adjuvant treatment
5FU-LV* 47 (61·04) 0 0
Xelox/Folox 0 76 (63·87) 41 (34·17)
No treatment 30 (38·96) 43 (36·13) 79 (65·83)
Disease-free survival
Patients with 
recurrence 22 (28·57) 18 (15·13) 21 (17·5)
Overall survival
nº of Exitus 13 (16·88) 11 (9·24) 15 (12·5)
*5-Fluorouracil (5FU)-Leucovorin (LV)
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Figure 1: 4-gene expression signature to predict DFS in early-stage CRC patients. Kaplan-Meier plots for 4-gene expression 
signature ColoLipidGene and p Log Rank value in the training group, validation groups I and II, and GSE39582 series from Gene Expression 
Omnibus Database are shown. (Training group: Low risk n = 55, High risk n = 22; Validation group I: Low risk n = 72, High risk n = 47; 
Validation group II: Low risk n = 63, High risk n = 57; Validation in public GSE39582 series: Low risk n = 165, High risk n = 95).
Table 3: Univariate cox regression analysis for disease-free survival of the clinical parameters in 
stage II CRC patients
Variable Univariate analysis
Training group Validation group I Validation group II
HR (95% CI) P HR (95% CI) P HR (95% CI) P
Age (continuous) 1 (0·96–1·05) 0·839 1·01 (0·98–1·05) 0·492 1 (0·96–1·04) 0·97
Age, > v ≤ 70 1·08 (0·46–2·52) 0·863 1·37 (0·53–3·54) 0·525 0·88 (0·34–2·26) 0·786
Sex, male v 
female 1·86 (0·76–4·56) 0·163 1·48 (0·57–3·82) 0·413 0·37 (0·14–0·96) 0·032
(Continued )
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Variable Univariate analysis
Training group Validation group I Validation group II
HR (95% CI) P HR (95% CI) P HR (95% CI) P
Location of 
primary 0·321 0·845 0·123
(Reference: 
Sigmoid colon 
and rectosigmoid 
junction)
Cecum and 
Ileocecal Valve NA 0·81 (0·18–3·7) 0·48 (0·06–3·6)
Acending 
colon and 
hepatic flexure
0·77 (0·28–2·07) 0·57 (0·16–2·07) 0·81 (0·27–2·43)
Transverse, 
splenic flexure 
and descending 
colon
1·57 (0·54–4·53) 0·79 (0·22–2·86) NA
Rectum
Grade/
Differentiation 0·585 0·457 0·319
(Reference: 
Moderate) Poor 2·07 (0·48–8·92) 1·51 (0·34–6·68) 2·36 (0·69–8·05)
Well 0·63 (0·08–4·72) 2·31 (0·66–8·1) 0·5 (0·07–3·74)
pT (T4 v T3) 1·75 (0·73–4·17) 0·223 3·19 (1·2–8·49) 0·016 3·42 (1·42–8·27) 0·011
Mean lymph 
nodes resected 
(continuous)
1·01 (0·95–1·08) 0·759 0·97 (0·91–1·04) 0·435 0·92 (0·85–0·99) 0·012
Range of lymph 
nodes examined, 
> v ≤ 12
1·74 (0·76–4·02) 0·196 0·56 (0·22–1·46) 0·230 0·27 (0·11–0·63) 0·003
Adjuvant 
treatment, yes 
v no
1·03 (0·43–2·45) 0·952 1·27 (0·45–3·58) 0·642 1·83 (0·54–6·26) 0.173
Vascular invasion, 
yes v no 1·08 (0·44–2·65) 0·866 3·08 (1·22–7·78) 0·020 4·44 (1·78–11·04) 0·004
Perineural 
invasion, yes v no 1·16 (0·39–3·43) 0·793 3·04 (1·2–7·72) 0·025 4·14 (1·69–10·13) 0·004
Bowel 
obstruction/
perforation, yes 
v no
3·07 (1·19–7·87) 0·034 1·59 (0·63–4) 0·328 4·15 (1·76–9·79) 0·002
Clinical classifier 
(ASCO risk*), 
High v Low risk
2·53 (0·59–10·81) 0·157 4·35 (0·6–554·13) 0·187 5·52 (1·28–23·73) 0·004
Abbreviations: NA, not available; HR (95% CI), hazard ratio and corresponding 95% confidence interval from univariate 
cox proportional hazards analysis; P, p value from univariate cox regression analysis; ASCO, American Society of Clinical 
Oncology.
*Patients are considered high risk if they have any of the following events: numbers of lymph nodes examined ≤ 12; T4; 
poor histologic grade; emergency presentation with obstruction or perforation; perineural or lymphovascular invassion.
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Table 4: Uni- and multivariate cox regression analysis for disease-free survival of ColoLipidGene signature and individual composing genes, and the clinical 
classifier (ASCO clinical risk criteria) in stage II CRC patients
Variable Training group Validation group I Validation group II
Low 
Risk
High 
Risk
Unadjusted Adjusted# Low 
Risk
High Risk Unadjusted Adjusted# Low Risk High 
Risk
Unadjusted Adjusted#
R N R N HR 
(95% CI)
P HR 
(95% CI)
P R N R N HR 
(95% CI)
P HR 
(95% CI)
P R N R N HR 
(95% CI)
P HR 
(95% CI)
P
ABCA1 7 43 15 34 3·08 (1·25–7·56) 0·010
3·76 
(1·4–10·08) 0·006 6 65 12 54
2.63 
(0.99–7) 0.045
3.12 
(1.1–8.82) 0.026 3 47 18 73
4.21 
(1.24–14.32) 0.007
5.05  
(1.44–17.65) 0.003
ACSL1 10 51 12 26 2.93 (1.26–6.81) 0.013
2.34 
(0.91–6.02) 0.082 5 61 13 58
3.12 
(1.11–8.76) 0.021
3.86  
(1.16–12.79) 0.017 2 29 19 91
3.35 
(0.78–14.4) 0.056
4.89  
(1.04–22.97) 0.018
AGPAT1 8 51 14 26 4.31 (1.8–10.32) 0.001
3.54 
(1.39–9) 0.007 4 52 14 67
3.11 
(1.02–9.47) 0.03
4.45  
(1.31–15.11) 0.009 3 40 18 80
3.24 
(0.95–11) 0.032
3.11 
(0.89–10.93) 0.049
SCD 3 26 19 51 3·57  (1·06–12·08) 0·018
3·13  
(0·9–10·93) 0·046 3 57 15 62
5.32  
(1.54–18.38) 0.002
4.08 
(1.12–14.9) 0.017 12 83 9 37
1.76 
(0.74–4.18) 0.208
2.17 
(0.85–5.57) 0.113
Clinical classifier 
(ASCO risk*); 
High v Low risk
2 14 20 63
2·53  
(0·59–
10·81)
0·157 0 13 18 106
4·35  
(0·6–
554·13)
0·187 2 40 19 80 5.52 (1.28–23.73) 0.004
ColoLipidGene; 
High v Low risk
9 55 13 22 4.65  (1.98–10.93)
< 
0·001
3.94  
(1.54–10.11) 0·005 4 72 14 47
6.57  
(2.15–20.02)
< 
0·001
6.55  
(2.06–20.75)
< 
0·001 5 63 16 57
3.88  
(1.42–10.59)
< 
0·005
6.89 
(2.05–23.19)
< 
0·001
Abbreviations: HR (95% CI), hazard ratio and corresponding 95% confidence interval from adjusted or unadjusted Cox regression analyses; P, p value from adjusted 
or unadjusted Cox regression analyses; N, Nº of patients in each risk group; R, Nº of patients with relapse; ASCO, American Society of Clinical Oncology.
*Patients are considered high risk if they have any of the following events: numbers of lymph nodes examined ≤ 12; T4; poor histologic grade; emergency 
presentation with obstruction or perforation; perineural or lymphovascular invassion.
#Cox regression analyses were adjusted for T stage, Vascular invassion, Perineural invassion, Bowel Obstruction/Perforation and Age > 70.
group 1. The multivariate analysis also confirmed 
ColoLipidGene as an independent prognostic classifier for 
DFS in the validation group I with 6.5-fold increased risk 
of relapse for stage II CRC patients [HR (95% CI): 6.55 
(2.06–20.75), p < 0.001; Table 4].
In order to further validate the prognostic strengthen 
of CololipidGene, we analyzed the expression levels of 
the metabolic-related gene signature in an independent set 
of 120 stage II CRC patients (validation group II) from 
hospitals located in different regions (Clinic University 
Hospital in Barcelona, La Fe University Hospital and 
Oncologic Institute of Valencia). Median follow-up and 
3-year DFS of this group of 120 patients was 58.3 months 
and 84% respectively. Twenty-one out of the 120 patients 
relapsed with local and/or distant metastasis (17.5%), of 
which 15 patients (71.43%) died due to CRC. 79 patients 
(65.83%) did not receive adjuvant treatment, whereas 41 
patients (34.17%) received chemotherapy (Table 2). As it 
is shown in Figure 1, ColoLipidGene prognostic value was 
further confirmed in this group of patients (c-index = 0.7), 
identifying stage II CRC patients with almost 7-fold higher 
risk of relapse 6.89 [HR (95% CI): 6.89 (2.05–23.19), 
p < 0.001; Table 4]. Similarly to the previously examined 
validation group 1, the 3-year DFS rates in the validation 
group 2 in patients from High risk group classified by 
ColoLipidGene was 73% (95% CI: 0.63–0.86) compared 
with 94% (95% CI: 0.88–1) in patients from low risk 
group in this group of stage II CRC patients.
Thus, ColoLipidGene was revealed as an independent 
prognostic classifier for DFS in all groups of stage II 
CRC patients, showing stronger power and accuracy than 
any other variables, including the currently used clinical 
classification. Of note, though to a lower extent, all genes 
defining ColoLipidGene combined biomarker constitutes 
individual biomarkers of prognosis of stage II-CRC 
patients (Figure 2), facilitating the interpretation of the 
results. Thus, after adjusting for potential confounding 
factors, the increased risk of relapse (pooled hazard ratios 
based on random-effects meta-analysis) for patients with 
increased levels of ABCA1, ACSL1, AGPAT1 or SCD was 
of HR (95% CI): 3.78 (2.03–7.03), p < 0.001; HR (95% 
CI): 3.14 (1.61–6.13), p < 0.001; HR (95% CI): 3.65 (1.93–
6.91), p < 0.001; and HR (95% CI): 2.81 (1.46–5.38), p = 
0.002 respectively. This is, higher levels of either ABCA1, 
ACSL1, AGPAT1 or SCD is associated with worse clinical 
outcome of the patients as independent molecular factors, 
further supporting the strength of their combined analysis 
as ColoLipidGene metabolic biomarker.
Additionally, to further validate the prognosis 
prediction ability of ColoLipidGene, we evaluate its 
prognostic value in public gene expression data of colon 
cancer patients from Gene Expression Omnibus Database. 
The public series was constituted for 566 patients with 
colon cancer, 264 out of the 566 with stage II colon cancer, 
including local and/or distant recurrence in 59 patients 
(22.34%). As it is shown in Figure 1, ColoLipidGene 
prognostic power was further confirmed in this group of 
independent stage II colon cancer patients (p Log Rank 
value < 0.005), identifying patients with almost 2-fold 
higher risk of relapse [HR (95% CI): 2.05 (1.23–3.42), 
p = 0.006]. 3-year DFS in patients from High risk group 
classified by ColoLipidGene was 73% (95% CI: 0.64–
0.82) compared with 86% (95% CI: 0.80–0.92) in patients 
from Low risk group in these group of stage II colon cancer 
patients from public database. These results obtained in 
four independent groups of stage II colon cancer patients 
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Figure 2: Prognostic value of individual genes constituting ColoLipidGene in the different group of patients. Kaplan-
Meier plots for individual genes of ColoLipidGene and p Log Rank value in the training group and validation groups I and II are shown.
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obtained in different time points and locations, confirm the 
potential use of these metabolic biomarker as a prognostic 
tool in early-stage colon cancer patients.
DISCUSSION
Currently, outcome prediction in CRC is based on 
TNM or Dukes staging classification system, insufficient 
for accurately predicting survival of stage II-CRC 
patients, in which chemotherapy administration is one of 
the decision to make in patient management. Thus, new 
biomarkers to better stratify and correctly prescribe the 
best treatment for precise patients to optimize outcome, 
reduce adverse toxicity events, reduce cost-effectiveness 
ratios is a necessary demand for early-stage CRC patients.
Several studies have recently proposed complex 
gene expression profiles to predict OS and DFS in 
CRC patients, but neither of them is focused on lipid 
metabolism [4–7]. Most of these proposed molecular 
biomarkers contain a large number of genes that might 
complicate the experimental application, with limited 
biological significance of the combination of genes that 
might also complicate the interpretation of results. Wang 
and colleagues developed a 23-gene expression signature 
studied in 74 stage II-CRC [15]. However, a completely 
different 30-gene expression signature was proposed by 
Barrier and colleagues in another group of stage II colon 
cancer patients by using the same Genechip and different 
results were obtained when they studied the predictive 
value of the 23-gene expression signature proposed by 
Wang and colleagues in their patients [16]. Oncotype 
Dx Colon Cancer test is based on mRNA expression of 
12 target genes, and was validated in a large clinical trial 
of primary CRC cases, finding clinical utility when used 
as a complement to T stage and mismatch repair status, 
specifically for patients who have T3, MMR-proficient, 
stage II disease [17, 18]. The ColoPrint gene signature 
uses 18 genes on a microarray platform. The classifier was 
applied in a training set (n = 188) of stage I, II and III, 
but they didn’t show significant prognostic value for DFS 
within each stage, and the robustness of the signature is 
awaiting evaluation in a prospective trial [6]. Currently, 
only one prognosis test for stage II and III CRC patients, 
the ColoGuidePro, has been designed with less than 
8 genes. However, this 7-gene expression signature only 
stratified stage III CRC patients, whereas prediction of 
relapse of stage-II patients was not validated [7]. Thus, 
evidence stand out the necessity of understanding the 
biological significance of a biomarker to properly applied 
obtained information, and recent research has been focused 
on defining molecular subtypes (including “mesenchymal” 
and “stem cell”) [19]. In this sense, different metabolic 
profiles might provide not only information regarding 
molecular subtypes related to energetic capacity of tumoral 
cells, but also might provide new therapeutic options 
involving the inhibition of these pathways, pointing at the 
putative clinical relevance of this study.
Altered cellular metabolism is considered an 
important hallmark of cancer [8] and several enzymes 
involved in lipid metabolism have been shown to be 
involved in tumor malignancy [11, 12]. Here, we analyzed 
for the first time the putative association between global 
expression of lipid metabolism-related genes and prediction 
of outcome in early-stage CRC patients. Results from 
three different groups of patients recruited within different 
time points and by hospitals located in different regions, 
and from public whole human genome Microarray data 
of colon cancer patients from Gene Expression Omnibus 
Database, point at activation of ABCA1, ACSL1, AGPAT1 
and SCD as main relevant metabolic factors in malignant 
progression. ATP-Binding Cassette Subfamily-A Member 
1 (ABCA1), identified as a major regulator of phospholipid 
homeostasis, is involved in transport of cellular cholesterol 
from peripheral cells and tissues. The expression of ABC 
transporters (including ABCA1) have been associated with 
deregulation in one of the most drug-resistant cancers, the 
pancreatic ductal adenocarcinoma (PDAC) [20]. In addition, 
reported data suggest that ABCA1 gene might contribute 
to a more aggressive growth of multiple drug resistant 
melanomas [21], and the individual association of ABCA1 
with a more aggressive phenotype of colorectal tumors has 
been also identified in an additional study focused on the 
relationship between metabolic syndrome and colorectal 
cancer (Vargas T et al., 2014) [22]. On the other hand, 
ACSL1 is an isozyme of Acyl-CoA synthetase (ACS) 
family, known to play an important role in lipid metabolism, 
cancer cell survival and apoptosis inhibition [11]. ACS 
converts long-chain fatty acids to acyl-CoA, a crucial step 
in several lipid metabolism pathways. Previous reports 
have indicated that other ACS isozymes, such as ACSL4 
and ACSL5, are overexpressed in various types of cancer, 
including colon adenocarcinoma [11, 14, 23–27]. Namely, 
Triacsin C (a potent inhibitor of ACS, including ACSL1 
[28]) induce massive apoptosis and selective cytotoxicity in 
cancer cells [11]. AGPAT1 encodes an enzyme that converts 
lysophosphatidic acid (LPA) into phosphatidic acid (PA), 
phospholipids involved in signal transduction and in lipid 
biosynthesis. While several studies have suggested the 
association between enhanced transcription of AGPAT2 
and certain cancers or inflammation-associated diseases, 
neither of them have described the influence of AGPAT1 
isoform on cancer prognosis [29]. Finally, the products 
of SCD (Stearoyl-CoA-desaturase 1) represent important 
precursors for the formation of complex lipids, and human 
SCD was found to be up-regulated in transformed cells and 
overexpressed in a variety of human cancers, being recently 
proposed as a potential target for cancer therapy [30]. These 
results suggest that activation of lipid metabolism through 
different metabolic steps is an essential event to facilitate 
early-stage tumor progression, probably due to both 
structural and energetic requirements of tumoral cells, as 
it has been previously proposed [12]. Thus, the combined 
activation of these four genes might ensure tumoral cells a 
competitive advantage through a quick supply of metabolic-
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related precursors through fatty acid and cholesterol 
metabolisms, and on the other hand avoiding lipidic-related 
toxicity through the alteration of the desaturase SCD.
We have identified a gene expression signature 
constituted of only 4 genes, as an independent prognostic 
biomarker of tumor progression for stage-II CRC patients, 
that exhibited better prognostic prediction within the same 
pathological stage even when compared with American 
Society of Clinical Oncology (ASCO) clinical risk criteria, 
suggesting its potential relevance as a complementary 
approach in clinical decision-making for this group of 
patients. Though further in vitro and in vivo work has 
still to be done to understand the contribution of ABCA1, 
ACSL1, AGPAT1 and SCD in tumor progression, it is 
important to note that the prognostic prediction ability 
of this profile was confirmed in different sets of cancer 
patients, including an independent series of public gene 
expression microarray data of colon cancer patients from 
Gene Expression Omnibus Database, reinforcing the 
relevance of ColoLipidGene as a reliable prognostic tool in 
stage II colon cancer patients. These results together with 
the reduced number of genes constituting the signature, 
the advantage of ColoLipidGene vs the other identified 
signatures lies on the fact that the four genes constituting 
ColoLipidGene are involved in a specific biological 
process (lipid metabolism), establishing an hypothesis that 
support the role of this signature in the aggressiveness of 
the tumors. Finally, ColoLipidGene is constituted by key 
metabolic “druggable” enzymes, pointing at them as main 
promising therapeutic targets for these patients.
MATERIALS AND METHODS
Study design and patients
80 stage II CRC patients undergoing surgery 
between 2000 and 2004 in La Paz University Hospital 
were enrolled in the training group for this retrospective 
study. Three of them were discarded because of the quality 
material obtained. Inclusion criteria: Age ≥ 18, completely 
resected rectal cancer or colon adenocarcinoma located at 
≥ 15 cm of the anal verge as determined by endoscopy or 
above the peritoneal reflection in the surgical resection, 
confirmed Stage II AJCC/UICC primary CRC and follow-
up of at least 36 months. Exclusion criteria: death within 
30 days after surgery, other cancers in previous 5 years 
and inflammatory bowel disease or specific gene-related 
cancer.
We validated the results in two different sets of 
patients. The validation group I was composed of 119 
stage II CRC patients recruited in different time period 
(between 2004 and 2008) from La Paz University 
Hospital (Madrid). Results were externally validated 
in an additional set of 120 patients with stage II CRC 
(validation group II) from Clinic University Hospital 
(Barcelona), La Fe University Hospital (Valencia) and 
the Oncologic Institute of Valencia (IVO). For all groups 
of patients, Formalin-Fixed, Paraffin-Embedded (FFPE) 
samples were obtained with the approval of the human 
research Ethics review Committee of the hospitals 
involved (HULP-PI-1452). Clinico-histopathological 
data of patients were prospectively collected on clinical 
history and were confirmed by oncologists of the 
hospitals implicated in this study. All FFPE samples were 
revised by an anatomic pathologist ensuring > 85% of 
tumoral cells in each sample. Patients in all groups were 
classified following the clinical risk criteria of American 
Society of Clinical Oncology (ASCO). Since all patients 
included were within the same clinicopathological 
stage II, this clinical classifier was considered as the 
standard for determining patient prognosis. No other 
reference standard is applicable in this study since on 
similar molecular biomarker is currently applied for CRC 
patients with these characteristics. The reference clinical 
classifier consider patients with high risk of relapse if 
any of the following events: numbers of lymph nodes 
examined ≤ 12; T4; poor histological grade; emergency 
presentation with obstruction or perforation; perineural 
or lymphovascular invasion [31].
Additionally, we tested the prognostic power 
of ColoLipidGene in public whole human genome 
Microarray data of colon cancer patients from Gene 
Expression Omnibus Database. Raw gene expression 
data corresponding to the GSE39582 series was 
downloaded from the source as original CEL files. The 
566 Affymetrix U133Plus2 arrays included in the dataset 
were processed together locally by using the aroma.
affymetrix R package [32]. Robust Multichip Average 
(RMA) method was applied for background correction and 
normalization. Thus, we selected the stage II colon cancer 
patients (n = 264) and evaluated the prediction ability of 
ColoLipidGene in these public gene expression series of 
colon cancer patients.
Gene expression assays
Samples were deparaffinated and total RNA was 
extracted using RNeasy FFPE Kit (Qiagen Gmbh, 
Germany). 1 μg of total RNA was reverse transcribed by 
High Capacity cDNA Archive Kit (Applied Biosystems) 
for 2 h at 37°C. A Taq-Man Low Density Array (Applied 
Biosystems) was specifically designed for this experiment 
and was composed of 70 lipid metabolism-related genes 
(Table 1). These 70 genes within all genes present in 
pathways related with lipid metabolism were selected due 
to their key role as master regulators of cell metabolism, 
key steps of interconnection among lipid pathways or 
their reported role in biological processes associated 
with cancer. Gene-expression assays were performed in 
a HT–7900 Fast Real time PCR. The geometric mean of 
the internal control genes (GAPDH and B2M) was used as 
endogenous control. RT-StatMiner software (Integromics® 
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Inc., Madison, USA) was used to detect and determine 
the quality control and differential expression analyses 
of data.
Statistical analysis
The primary endpoint of the study was the 
relationship between gene expression and disease-free 
survival (DFS). Quantification of gene expression was 
calculated with the 2–ΔCt method. Time to relapse was 
obtained for the analysis of 3-year DFS, defined from the 
time of surgical procedure. The Kaplan-Meier method 
was used to estimate DFS. Log-rank test for Univariate 
Cox regression analysis was performed to test association 
between DFS and individual gene expression. To assess 
the effect on survival with adjustment for potential 
confounding factors, proportional hazards Cox regression 
modeling was used. Multivariate analysis included only 
variables that were significant (p < 0.05) in the Univariate 
analysis and age > 70 as main nonmodifiable risk factor. 
Hazard ratios (HR) and 95% CI were calculated from the 
Cox regression model. The threshold for dichotomization 
of the expression data of each gene into a low and a 
high value was selected based on the cutoff point with 
largest prediction ability, evaluated by the c-index using 
100 times 5-fold cross-validation (CV). Data were blind 
and independently analyzed by two different groups of 
experts in the field (Biostatistics and Bioinformatics Unit, 
IMDEA Food Institute and Bioinformatics and Functional 
Genomics Research Group, Cancer Research Center 
(CSIC-USAL).
The prognostic gene expression signature was 
developed analyzing the prediction ability for all possible 
Cox regression models with genes found within the range 
of significance in the univariate analysis, and selecting 
the multivariate model with largest c-index (> 0.75) 
implemented using 100 times 5-fold CV [33]. The 
threshold value was chosen such that the frequency of the 
high risk group was as the “observed recurrence risk”. 
Determined threshold value in the training set of patients 
was further applied to validation sets of patients. All 
reported p values were two-sided. Statistical significance 
was defined as p < 0.05. The statistical analyses were 
done by use of the R statistical software v2.15 (http://
www.r-project.org).
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